Company Overview of Biotie Therapies AG
Biotie Therapies AG offers drug development services focusing on neurology and psychiatry. Its SYN-118 product is a therapy for advanced Parkinson's disease patients. The company also provides clinical development programs and research services. It has a strategic partnership with UCB SA. Biotie Therapies AG was formerly known as Synosia Therapeutics AG and changed its name to Biotie Therapies AG in February 2011. As a result of its acquisition by Biotie Therapies Oyj, the name of Synosia Therapeutics AG was changed. The company was founded in 2005 and is based in Basel, Switzerland. As of February 2, 2011, Biotie Therapies AG operates as a subsidiary of Biotie Therapies Corp.
Founded in 2005
41 61 206 92 02
41 61 206 92 01
Key Executives for Biotie Therapies AG
Similar Private Companies By Industry
|Merck Sharp & Dohme Chibret A.G.||Europe|
|Joint Development Vehicle||Europe|
|Spirig Pharma AG||Europe|
|Sigma-Tau Pharma AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Biotie Therapies AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.